Autolus Therapeutics/$AUTL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Autolus Therapeutics

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Ticker

$AUTL
Primary listing

Industry

Biotechnology

Employees

649

AUTL Metrics

BasicAdvanced
$671M
-
-$0.89
1.76
-

Bulls say / Bears say

Autolus Therapeutics received FDA approval for AUCATZYL® (obecabtagene autoleucel) in November 2024, marking a significant milestone in its commercialization efforts. (autolus.gcs-web.com)
The company is expanding its pipeline into autoimmune diseases, with the CARLYSLE Phase 1 trial in systemic lupus erythematosus (SLE) expected to present initial data in Q1 2025. (autolus.gcs-web.com)
Autolus has secured a $30 million milestone payment from Blackstone upon FDA approval of AUCATZYL®, bolstering its financial position. (autolus.gcs-web.com)
In Q1 2025, Autolus reported a net loss of $70.2 million, with increased commercialization expenses leading to negative gross margins. (ainvest.com)
The safety profile of AUCATZYL® includes risks such as cytokine release syndrome (CRS) and neurotoxicities, which may impact patient adoption and regulatory scrutiny. (ainvest.com)
Autolus' cash reserves decreased to $516.6 million in Q1 2025, with a notable $20 million delay in U.K. R&D tax credits, raising concerns about cash flow sustainability. (ainvest.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AUTL

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs